-Nabriva Therapeutics (NASDAQ:NBRV) and Sinovant Sciences' antibiotic lefamulin was non-inferior to moxifloxacin in a phase 3 study, according to top-line results.
-In a modified intent to treat (mITT) population, the clinical response success rates were 76.8% for lefamulin and 71.4% for moxifloxacin.
-Also, Sinovant inked an agreement with a Chinese subsidiary of Sumitomo Dainippon Pharma (OTCPK:DNPUF) to acquire development and commercialization rights for lefamulin in Greater China. Nabriva shares are up 40.5% to $2.08 in after-hours trading.